HK1144684A1 - 融合多肽及其治療應用 - Google Patents
融合多肽及其治療應用Info
- Publication number
- HK1144684A1 HK1144684A1 HK10110734.8A HK10110734A HK1144684A1 HK 1144684 A1 HK1144684 A1 HK 1144684A1 HK 10110734 A HK10110734 A HK 10110734A HK 1144684 A1 HK1144684 A1 HK 1144684A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- igf
- igf1
- component
- fusion
- fusion polypeptides
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 101150088952 IGF1 gene Proteins 0.000 title 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64222905P | 2005-01-07 | 2005-01-07 | |
US65658305P | 2005-02-25 | 2005-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1144684A1 true HK1144684A1 (zh) | 2011-03-04 |
Family
ID=42634965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10110734.8A HK1144684A1 (zh) | 2005-01-07 | 2010-11-18 | 融合多肽及其治療應用 |
Country Status (13)
Country | Link |
---|---|
US (4) | US7396918B2 (zh) |
EP (2) | EP2241575B1 (zh) |
JP (1) | JP4988599B2 (zh) |
AT (1) | ATE517120T1 (zh) |
AU (1) | AU2006203882B2 (zh) |
CA (1) | CA2594023C (zh) |
DK (1) | DK2241575T3 (zh) |
ES (1) | ES2541810T3 (zh) |
HK (1) | HK1144684A1 (zh) |
HU (1) | HUE027645T2 (zh) |
PL (2) | PL1833847T3 (zh) |
PT (1) | PT2241575E (zh) |
WO (1) | WO2006074390A2 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
NZ572708A (en) | 2006-06-09 | 2011-11-25 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
MX2009001691A (es) * | 2006-08-31 | 2009-02-25 | Hoffmann La Roche | Metodo para produccion del factor de crecimiento i tipo insulina. |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
GB0715213D0 (en) * | 2007-08-06 | 2007-09-12 | Asterlon Ltd | Igf-1 |
EP3778652A1 (en) * | 2008-05-07 | 2021-02-17 | BioMarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
WO2010088502A2 (en) * | 2009-01-30 | 2010-08-05 | The Regents Of The University Of California | Insulin-like growth factor signaling and integrin |
US7963705B2 (en) * | 2009-02-24 | 2011-06-21 | Avago Technologies Fiber Ip (Singapore) Pte. Ltd. | Molded interconnect device (MID) optical connector with metal retaining clip |
TWI490371B (zh) | 2009-07-28 | 2015-07-01 | Industrie De Nora Spa | 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法 |
BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
US20130274235A1 (en) * | 2010-10-08 | 2013-10-17 | The General Hospital Corporation | Treatment of motor neuron disease |
CN102618575A (zh) * | 2011-09-16 | 2012-08-01 | 江苏普罗赛生物技术有限公司 | 哺乳动物细胞大规模生产重组人IGF1-Fc融合蛋白的实验技术 |
ES2738641T3 (es) * | 2012-12-18 | 2020-01-24 | Novartis Ag | Producción de proteínas terapéuticas en células de mamífero modificadas genéticamente |
PL2935320T3 (pl) | 2012-12-18 | 2020-03-31 | Novartis Ag | Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
CN105792839A (zh) | 2013-10-02 | 2016-07-20 | 诺华股份有限公司 | 用于治疗的胰岛素样生长因子拟似物 |
UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
US20170248609A1 (en) | 2014-01-27 | 2017-08-31 | Novartis Ag | Biomarkers predictive of muscle atrophy, method and use |
WO2016115171A1 (en) * | 2015-01-16 | 2016-07-21 | The Regents Of The University Of California | Insulin-like growth factor 2 (igf2) signaling and modulation |
CA3000742A1 (en) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
ES2909074T3 (es) * | 2016-05-06 | 2022-05-05 | Phasebio Pharmaceuticals Inc | Proteínas de fusión ELP para liberación controlada y sostenida |
EP3609522A4 (en) * | 2017-04-10 | 2021-05-05 | Yoram Palti | METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES |
EP3453722A1 (en) * | 2017-09-06 | 2019-03-13 | Julius-Maximilians-Universität Würzburg | Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase |
CN113214410A (zh) * | 2017-11-04 | 2021-08-06 | 海南大学 | 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法 |
EP3569614A1 (en) * | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
WO2020006273A1 (en) * | 2018-06-27 | 2020-01-02 | Juvena Therapeutics, Inc. | Heparin-associated polypeptides and uses thereof |
CA3154189A1 (en) * | 2019-10-10 | 2021-04-15 | Hung Do | Variant igf2 constructs |
EP4228675A1 (en) * | 2020-10-13 | 2023-08-23 | Betavive Ltd. | Method and compounds for treating diabetes and associated metabolic diseases |
WO2023214833A1 (ko) * | 2022-05-04 | 2023-11-09 | 이뮤노포지 주식회사 | Glp-1, 면역글로불린 fc, 및 igf-1을 포함하는 융합단백질 및 이의 용도 |
GB202216503D0 (en) * | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0429586B1 (en) * | 1989-06-09 | 1995-08-02 | Gropep Pty. Ltd. | Growth hormone fusion proteins |
IE912528A1 (en) * | 1990-07-19 | 1992-01-29 | Scripps Clinic Res | Inhabition of mac-1 receptor binding fibrinogen using d30¹homologs |
CA2135306A1 (en) * | 1992-05-08 | 1993-11-25 | Bradford A. Jameson | Igf-1 analogs |
SE9402332D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | Igf-1 |
US5622932A (en) * | 1995-05-05 | 1997-04-22 | Eli Lilly And Company | IGF-1 superagonists |
US6413740B1 (en) | 1995-12-15 | 2002-07-02 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
US5814478A (en) | 1995-12-15 | 1998-09-29 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
AUPP298498A0 (en) | 1998-04-17 | 1998-05-07 | Gropep Pty Ltd | Matrix binding factor |
ATE284415T1 (de) | 1999-01-06 | 2004-12-15 | Genentech Inc | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
DK2377413T3 (en) | 2007-07-23 | 2017-05-01 | Reynolds Tobacco Co R | Smokeless tobacco compositions and methods of treating tobacco for use therein |
-
2006
- 2006-01-06 HU HUE10007017A patent/HUE027645T2/en unknown
- 2006-01-06 JP JP2007550507A patent/JP4988599B2/ja not_active Expired - Fee Related
- 2006-01-06 EP EP10007017.6A patent/EP2241575B1/en active Active
- 2006-01-06 PL PL06717668T patent/PL1833847T3/pl unknown
- 2006-01-06 AU AU2006203882A patent/AU2006203882B2/en not_active Ceased
- 2006-01-06 ES ES10007017.6T patent/ES2541810T3/es active Active
- 2006-01-06 AT AT06717668T patent/ATE517120T1/de active
- 2006-01-06 CA CA2594023A patent/CA2594023C/en not_active Expired - Fee Related
- 2006-01-06 PT PT100070176T patent/PT2241575E/pt unknown
- 2006-01-06 PL PL10007017T patent/PL2241575T3/pl unknown
- 2006-01-06 WO PCT/US2006/000495 patent/WO2006074390A2/en active Application Filing
- 2006-01-06 DK DK10007017.6T patent/DK2241575T3/en active
- 2006-01-06 EP EP06717668A patent/EP1833847B1/en active Active
- 2006-01-06 US US11/327,555 patent/US7396918B2/en active Active
-
2008
- 2008-06-06 US US12/134,301 patent/US7837999B2/en not_active Expired - Fee Related
-
2010
- 2010-09-30 US US12/894,278 patent/US8158581B2/en not_active Expired - Fee Related
- 2010-11-18 HK HK10110734.8A patent/HK1144684A1/zh not_active IP Right Cessation
-
2012
- 2012-03-09 US US13/416,481 patent/US8445434B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1833847A2 (en) | 2007-09-19 |
EP1833847B1 (en) | 2011-07-20 |
AU2006203882A1 (en) | 2006-07-13 |
JP2008526233A (ja) | 2008-07-24 |
CA2594023C (en) | 2015-07-14 |
AU2006203882B2 (en) | 2011-05-12 |
US7396918B2 (en) | 2008-07-08 |
ES2541810T3 (es) | 2015-07-24 |
ATE517120T1 (de) | 2011-08-15 |
DK2241575T3 (en) | 2015-08-24 |
EP2241575A1 (en) | 2010-10-20 |
PL1833847T3 (pl) | 2011-12-30 |
PL2241575T3 (pl) | 2015-12-31 |
US20060166328A1 (en) | 2006-07-27 |
HUE027645T2 (en) | 2016-10-28 |
US20110020342A1 (en) | 2011-01-27 |
EP2241575B1 (en) | 2015-06-24 |
WO2006074390A3 (en) | 2007-01-11 |
US8158581B2 (en) | 2012-04-17 |
PT2241575E (pt) | 2015-09-16 |
US20090069235A1 (en) | 2009-03-12 |
US8445434B2 (en) | 2013-05-21 |
JP4988599B2 (ja) | 2012-08-01 |
US7837999B2 (en) | 2010-11-23 |
US20120195896A1 (en) | 2012-08-02 |
CA2594023A1 (en) | 2006-07-13 |
WO2006074390A2 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1144684A1 (zh) | 融合多肽及其治療應用 | |
HUS1500024I1 (hu) | GLP-1 analóg fúziós proteinek | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
IL161016A (en) | Polypeptides capable of ang-2 binding | |
SG158141A1 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
EP1699920A4 (en) | NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL | |
MX353234B (es) | Variantes de polipeptidos con función efectora alterada. | |
WO2003058203A3 (en) | Extended glucagon-like peptide-1 analogs | |
IL169820A0 (en) | Amino acids with affinity for the alpha-2-delta-protein | |
WO2005077981A3 (en) | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES | |
CZ2014740A3 (zh) | ||
WO2004078778A3 (en) | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF | |
MXPA02012106A (es) | Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion. | |
WO2006031370A3 (en) | Polypeptide variants with altered effector function | |
ATE542137T1 (de) | Immunocytokine mit modulierter selektivität | |
WO2007035600A3 (en) | Natriuretic activities | |
WO2007071692A3 (en) | Immunogenic composition | |
WO2007047504A3 (en) | Natriuretic peptide modified transferrin fusion proteins | |
WO1999003881A3 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
WO2002060978A1 (fr) | Polyalkylene glycols ramifies | |
WO2004087874A3 (en) | Novel nucleic acids and polypeptides | |
WO2004043403A3 (en) | Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use | |
WO2005069726A3 (en) | Hybrid and chimeric polypeptides that regulate activation of complement | |
AP2006003544A0 (en) | Amino acids with affinity for the alpha2delta-protein. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210103 |